Vidya has announced that new clinical research studying its ingredient NūGensia in adults with prediabetes has been published.
The research, published in EC Nutrition, evaluated the effects of Vidya’s proprietary Akkermansia muciniphila strain (VHAKM) on metabolic health indicators, including blood glucose levels and body weight.
The company said in its statement that the publication “marks a significant milestone,” adding peer-reviewed human clinical evidence to the growing body of science supporting Akkermansia muciniphila.
The study
The trial involved 60 adults aged 31-60 with prediabetes, who were randomised to receive either NūGensia (10 billion CFU) or a placebo daily for a 60-day period.
At the end of the trial, the NūGensia group had significant reductions in fasting and postprandial blood glucose, HbA1c and triglycerides, along with improvements in body weight, BMI, waist circumference and diastolic blood pressure.
NūGensia was also found to be safe and well-tolerated, with no adverse events reported.
“These findings establish Akkermansia muciniphila as a clinically validated, next-generation probiotic for metabolic health, offering a natural and effective strategy to support glucose balance, weight management and overall metabolic wellbeing,” said Subhendu Nayak, Director of R&D, Probiotics, Vidya.
NūGensia is developed using Vidya’s proprietary, patent-pending delivery system.
This system utilises a starch-based protective shell that shields the live Akkermansia muciniphila strain from oxygen exposure during both production and storage.
By addressing a significant stability challenge, this process enhances the commercial viability of Akkermansia as an ingredient.
